Indian Pharma Firms Rattled by Trump's Proposed 200% Tariff on Generic Drugs

US President Donald Trump has proposed imposing tariffs as high as 200% on generic pharmaceutical imports, sending shockwaves through the pharma industry. Indian generic drug manufacturers, who are major suppliers to the US market, are among those most affected by the uncertainty. Reports indicate a potential two-year transition window may be part of the policy framework, offering limited relief to companies. The move has left pharmaceutical firms scrambling to assess the financial and operational impact of such steep duties. Industry stakeholders are closely monitoring developments as details of the tariff plan continue to emerge.